Skip to Content

Cinqair (reslizumab) Disease Interactions

There are 2 disease interactions with Cinqair (reslizumab):

Major

Reslizumab (applies to Cinqair) anaphylaxis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Asthma

Anaphylaxis to reslizumab was reported in 0.3% of asthma patients in clinical studies. These events were observed during or within 20 minutes after completion of the infusion and reported as early as the second dose of therapy. Patients should be observed for an appropriate period of time after reslizumab administration. If severe systemic reactions, including anaphylaxis, occur, stop administration immediately and provide appropriate medical treatment. Discontinue reslizumab use permanently if the patient experiences signs or symptoms of anaphylaxis.

Moderate

Interleukin inhibitors (applies to Cinqair) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

There have been reports of serious infections, including infections with opportunistic pathogens, and reactivation of latent infections in patients receiving interleukin inhibitors. Treatment with these agents should not be initiated in patients with an active infection until the infection resolves or is adequately treated. Caution is recommended when considering the use of interleukin inhibitors in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.